Holen Sie sich die Stockscreener-App
9.52
3.35%
-0.33
Handel nachbörslich:
9.50
-0.02
-0.21%
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Corvus Pharma Q2 2026 Earnings Call Transcript - Benzinga
Other investing cash flow items (total) of Corvus Pharmaceuticals, Inc. – FWB:C17 - TradingView
Corvus Pharmaceuticals Inc. R (C17.HA) analyst ratings, estimates and forecasts - Yahoo Finance UK
Corvus Pharma Com (CRVS-Q) Stock Price and News - The Globe and Mail
Corvus Pharmaceuticals Announces Initiation of Phase 1b - GlobeNewswire
One drug is now in trials for four conditions, including a skin disease. - stocktitan.net
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa - Yahoo! Finance Canada
Corvus Pharmaceuticals,Primary Endpoint Is - Moomoo
Enterprise value of Corvus Pharmaceuticals, Inc. – HAN:C17 - TradingView
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In? - Yahoo! Finance Canada
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
Corvus Pharmaceuticals at cantor global healthcare: pipeline bets widen By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals at cantor global healthcare: pipeline bets widen By Investing.com - Investing.com India
Corvus Pharmaceuticals at cantor global healthcare: pipeline bets widen By Investing.com - Investing.com Canada
Trial Results Published Could Be A Game Changer For Corvus Pharmaceuticals (CRVS) - simplywall.st
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference - marketscreener.com
A biotech company's live healthcare talk is set for Sept. 10. Its webcast stays online 90 days. - Stock Titan
Corvus Pharmaceuticals Inc. (CRVS) Peer Comparison – Compare with Others - valueresearchonline.com
Corvus Pharmaceuticals (CRVS) Declines 3.8% to $14.16 as Stock Tests Key Support at $13.45NHNL Divergence - vinanet.vn
Corvus Pharmaceuticals (CRVS) Declines 3.8% to $14.16 as Stock Tests Key Support at $13.45Put Call Ratio - dars.gov.et
Corvus Pharmaceuticals Publishes Blood Data Showing Soquelitinib Activity in T Cell Lymphoma and Supporting Ongoing PTCL, Atopic Dermatitis Trials - quiverquant.com
Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment - Seeking Alpha
Corvus Pharmaceuticals Publishes Blood Data Showing Soquelitinib Activity in T Cell Lymphoma and Supporting Ongoing PTCL, Atopic Dermatitis Trials - Quiver Quantitative
Corvus lymphoma study: 67% were alive at 24 months after 1-3 prior therapies - stocktitan.net
Corvus Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRVS - TradingView
Blue Owl Capital Holdings LP Takes Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)? - simplywall.st
Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)? - simplywall.st
637,500 Shares in Corvus Pharmaceuticals, Inc. $CRVS Bought by DCF Advisers LLC - MarketBeat
Corvus (CRVS) Q2 2026 Results: The EPS Result Is Below Expectation; Market Response: The Stock Records a 3.84% Increase in the Current UpdateFinancial Health Score - vinanet.vn
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting - finance.yahoo.com
Corvus Pharmaceuticals (CRVS) Reports A Wider Loss, Is The Stock Still Cheap? - Sahm
Corvus Pharmaceuticals Stock Price Forecast. Should You Buy CRVS? - StockInvest.us
Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value (NASDAQ:CRVS) - Seeking Alpha
HC Wainwright Issues Negative Estimate for CRVS Earnings - MarketBeat
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
HC Wainwright Brokers Decrease Earnings Estimates for CRVS - MarketBeat
The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement - Seeking Alpha
Corvus Pharmaceuticals (CRVS) Pulls Back 3% as Biotech Volatility PersistsOvervalued Signals - vinanet.vn
Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss? - Sahm
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Corvus Pharmaceuticals Loss Widens to $18 Million as Soquelitinib Trial Costs Soar - finance.biggo.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss - MarketBeat
2.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):